Temsirolimus as Base Immunosuppressant for a Recipient With Metastatic Renal Cancer: Adequate Immunosuppression and Oncological Control—Case Report

Renal Cell Carcinoma and Kidney Transplantation: A Narrative Review

“…No treatment, an introduction of mTOR inhibitor, and/or therapy with TKI are all valid options. No trial evidence exists for TKI in KTRs, few case reports show effect in localized 99,100 and metastatic [101][102][103] disease, though as for immune checkpoint inhibitors, toxicity may limit treatment. 104,105 Based on the current available data, we present our suggested recommendations as an overview in Figure 3 and with details in Table 3.…”